Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)
Several clarifications are important for interpreting this table
When taking semaglutide, avoiding these processed versions protects your blood glucose stability and prevents rapid insulin spikes that can reduce the medication's appetite-suppressing benefits
Monitor Symptoms Closely: If you do use antacids, pay close attention to whether your symptoms are improving
Always confirm directly with your insurer
